Repligen Corporation

What they do

Repligen develops and commercializes bioprocessing products that increase efficiency and flexibility in the manufacturing of biological drugs. Its product suite serves both upstream and downstream processes, primarily for large biopharmaceutical companies and contract development and manufacturing organizations (CDMOs). The company operates as one bioprocessing business with a diversified portfolio built through organic innovation and targeted acquisitions.

Revenue drivers

• Bioprocessing products — Comprehensive suite of products for upstream and downstream biological drug manufacturing, sold to large biopharma and CDMOs.

Recent performance

Q2 2026 revenue was $204 million, up 12% as reported and 13% organic year-over-year. GAAP operating income was $14 million (flat), adjusted operating income rose 55% to $34 million. GAAP EPS was $0.09, adjusted EPS $0.54. Revenue for the first half of 2026 was $398.4 million (Q1 $194.3M + Q2 $204.1M). Full-year 2025 revenue was $738.3 million with net income of $48.9 million.

Strategy

Management emphasizes portfolio diversification, disciplined execution, and market outperformance. They are investing in customer-facing infrastructure, including a new Repligen Training & Innovation Center in Breda, the Netherlands. The company announced a definitive agreement to acquire BioLife Solutions for approximately $1.5 billion (64% stock, 36% cash) to expand into cell therapy tools and biopreservation media. They also completed the acquisition of 908 Devices' desktop portfolio for process analytics in March 2025. The company continues to pursue both organic growth and targeted acquisitions.

Risks

• Customer concentration — Historical reliance on a limited number of large customers could hurt revenue if any customer reduces orders.
• Supplier concentration — The company relies on a limited number or single suppliers for certain products, and disruption could materially affect operations.
• Manufacturing execution — Inability to manufacture products in sufficient quantities or timely manner could reduce revenue and harm gross margin.
• Tariff and trade policy uncertainty — A U.S. Supreme Court decision invalidating IEEPA-based tariffs creates uncertainty around future trade actions and costs.

Outlook

Management raised full-year 2026 organic revenue growth guidance to 10.5%-13.5% and adjusted EPS to $2.03-$2.09. They cite strong first-half results and improved line of sight to the second half. The BioLife acquisition is expected to close in Q4 2026 and is described as accretive to revenue growth, margin, and adjusted EPS.